Analysis of these markers in individuals with MS (N = 70) and without MS (N = 24) showed significant expression differences for PTGS2 (4.13±0.51 vs 2.73±0.54; p = 0.008) and VEGFA (1.59±0.09 vs 1.38±0.10; p = 0.006). This evidence concerns the gene VEGFA and myeloid sarcoma.